anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants in the active control will receive a modified single session BASICS. BASICS is a well-documented and empirically supported prevention/intervention program for college student drinkers. BASICS targets heavy drinking students that have experienced or are at an increased risk for a variety of alcohol-related problems linked to college student life. The program is designed to help students make better alcohol-use decisions based on a broader understanding of the risks associated with problem drinking. It enhances motivation to change and promotes the development of skills to moderate drinking. The overall style of the program uses motivational interviewing and emphasizes empathy and non-judgmental interaction. The aims of BASICS are to (1) reduce alcohol consumption and consequences, (2) promote healthier and more responsible choices, and (3) provide information and coping skills.
PURPOSE:To obtain a preparation for nasal administration efficiently absorbing interferon from nasal mucosa, low damage of nasal mucosa tissue and high safety, containing an interferon and a sucrose fatty acid ester. CONSTITUTION:An interferon preparation for nasal administration containing an interferon (e.g. interferon alpha, interferon beta or interferon gamma) and a sucrose fatty acid ester as an absorption promoter. A sucrose fatty acid ester comprising 8-22C, especially preferably 12-18C fat component, an ester constituent component thereof is used as the sucrose fatty acid ester. The amount of the interferon blended in the preparation is about 10<3>-10<9> international unit(IU). The concentration of the sucrose fatty acid ester blended is usually 0.05w/v%-10w/v%, preferably 0.1-5.0w/v%.
Acemannan has now been discovered to be a potent inducer of Interleukin 1 (Il-1) and prostaglandin E2 (PGE2) production by human peripheral blood adherent cells in culture. Il-1 has been shown to be an important macrophage product and is associated with influencing the activity and product production of T lymphocytes, fibroblasts, B lymphocytes and endothelial cells. Acemannan has no demonstrated toxicity, and acts as an adjuvant and immunoenhancer. Administration of an amount of acemannan sufficient to stimulate monocytes and macrophages not only produces Il-1 and PGE2 but also stimulates phagocytosis, increases antibody production, enhances antiviral activity in the serum and, in those patients with AIDS/ARC, produces defective HIV virus. Acemannan has been shown to affect the rate of virus production in viral vaccine master seed cultures by accelerating the rate of viral replication. In addition, acemannan is a potent adjuvant to viral vaccines in chickens. Acemannan has also shown specific antitumor activity against sarcoid tumors in horses.
Subjects in the control group will only receive sham (placebo) injection three successive times with and interval of 21days between each injection, similar to the timepoints of (i-prf) injection in the intervention group. Also the sites of injection will be similar to the sites of injection of the intervention group; 1 ml of the placebo agent will be injected intraligamentally distal to the right and left canines, and 0.5 ml will be injected intraligamentally palatal to each incisor. An anesthetic solution will be administered for pain control before the administration of the sham injections.
The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-L-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy- induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.
PCT No. PCT/US94/06128 Sec. 371 Date Jun. 1, 1994 Sec. 102(e) Date Jun. 1, 1994 PCT Filed Jun. 1, 1995 PCT Pub. No. WO94/27643 PCT Pub. Date Dec. 8, 1994The invention provides retroviral vectors which can be used for directing gene delivery to a specific sub-population of mammalian cells. The vectors comprise chimeric targeting proteins which specifically alter the host range of the vector. The chimeric targeting proteins contain a ligand moiety which is capable of binding to receptors present on target cells, and an uptake moiety which is capable of promoting entry of the vector into the target cell. The ligand moiety is derived from a cytokine that acts upon the target cells of interest, and the uptake moiety is derived from a retroviral envelope protein.
INTRODUCTION: Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions. Cervical dystonia (CD) is the most common focal dystonia. There are several instruments assessing the symptoms of CD. However, different scales assess different features which may lead to poor patient evaluation.
AIM: The aim of the study was to evaluate the degree of overlap of most often used CD rating scales identified by the literature review.
METHODS: A thorough search of the Medline database was conducted in September 2021. Then the frequency of each scale was calculated, and 7 most common scales were included in the content overlap analysis using Jaccard index (0 - no overlap, 1 - full overlap).
RESULTS: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), Tsui score, Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS), Cervical Dystonia Impact Profile 58 (CDIP-58), Craniocervical Dystonia Questionnaire 24 (CDQ-24), Cervical Dystonia Severity Rating Scale (CDSS), Cervical Dystonia Severity Rating Scale (DDS) and The Dystonia Non-Motor Symptoms Questionnaire (DNMSQuest) were the most common scales. 91 CD symptoms were distinguished from 134 items used in the scales. The mean overlap among all scales was 0.17. 52 (62%) symptoms were examined by more than one scale. The CIDP-58 captured the highest number of symptoms (63.0%), while the CDSS captured the lowest number (8.0%). None of the symptoms were examined by seven instruments.
CONCLUSIONS: There was a very weak overlap among scales. High inconsistency between the scales may lead to highly different dystonia severity assessment in clinical practice. Thus, the instruments should be combined.
The invention provides a fast dissolving film agent for treating erectile dysfunction and a preparation method thereof, wherein the drug for treating erectile dysfunction is tadalafil, avanafil, vardenafil, sildenafil citrate and eucranafil; the instant film agent is an oral instant film agent, and the film agent comprises the following components (by weight percent): 10-25% of main drug; 35-60% of polyvinyl alcohol; 5 to 15 percent of high-substituted hydroxypropyl cellulose; 5-10% of a plasticizer; 10-30% of a filler; 1 to 8 percent of water. The preparation method comprises the steps of preparing the film agent by a solvent casting method and then pressing. The invention has the key points that 1, the medicine is convenient to take, can be quickly taken, takes effect quickly, improves the bioavailability and has no first-pass effect. 2. The high-substituted hydroxypropyl cellulose is creatively adopted as a film forming material, so that the preparation has good forming performance, is not adhered, and does not influence the stability of the medicine. 3. The film agent is pressed, which is beneficial to improving the stability of the medicine.
An epidemic investigation system adapted to track epidemic prevention includes a server, a mobile device connected to the server, and at least one access control device connected to the server. The server includes a database, an input unit connected to the database and adapted to build data, a barcode generating unit connected to the database, and a searching unit connected to the database. The barcode generating unit is adapted to create a user barcode related to personal information of each user and a position barcode related to location information thereof. The user barcode serves to control access to an entrance and an exit of a region. The position barcode serves to arrange and manage locations in a region. Accordingly, the user barcode and the location barcode are used to record and track the user for executing the epidemic investigation quickly and precisely and saving labor costs.
All the 12 subjects enrolled in the study were exposed to at least one dose of GSK1360707 15 mg, 30 mg, 60 mg, 90 mg, 120 mg and 150 mg. All the subjects completed the study. The initial dose, given in the study as a single-dose was 15 mg GSK1360707. The remaining subjects were dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose did not exceed 150 mg per day, the maximum total dose given in the FTIH study.
PURPOSE:To produce titled glass adequate as a dental material without generation of voids, cracks, etc. and with good spread of a melt to a casting mold by incorporating an Li2O component and F atoms to the compsn of a ternary component system of CaO-Al2O3-P2O5. CONSTITUTION:This crystallized CaO-Al2O3-P2O5 glass is formed by incorporating 0.01-5pts.wt. Li2O and <=3pts.wt. F atoms by 100pts.wt. in total of 10-60wt% CaO, 5-35wt% Al2O3 and 25-85wt% P2O5 into CaO-Al2O3-P2O5 stock composed of the respective above-mentioned compsn. The solubility of Al2O3 is improved by incorporating the F atoms into the compsn of a ternary component system of CaO-Al2O3-P2O5. Further, the Li2O component is added to such compsn. to decrease the viscosity of the melt and to lower the softening point of the glassy casting and the crystallization temp. of calcium phosphate, by which the crystal of Al2O3.P2O5 is thoroughly developed and the difference in the specific gravity before and after the crystallization is eliminated to prevent the generation of the voids and cracks. This glass is adequate as the dental material such as artificial fang.
The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge and the protocol of physiotherapy by the physiotherapists of HCPA twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
Fred Brauer was an eminent mathematician who studied dynamical systems, especially differential equations. He made many contributions to mathematical epidemiology, a field that is strongly connected to data, but he always chose to avoid data analysis. Nevertheless, he recognized that fitting models to data is usually necessary when attempting to apply infectious disease transmission models to real public health problems. He was curious to know how one goes about fitting dynamical models to data, and why it can be hard. Initially in response to Fred's questions, we developed a user-friendly R package, fitode, that facilitates fitting ordinary differential equations to observed time series. Here, we use this package to provide a brief tutorial introduction to fitting compartmental epidemic models to a single observed time series. We assume that, like Fred, the reader is familiar with dynamical systems from a mathematical perspective, but has limited experience with statistical methodology or optimization techniques.
BACKGROUND: Obesity and mental health issues are two of the most prevalent global public health issues for a significant portion of people. The purpose of this study was to investigate the relationship between obesity indicators and mental health in Tehran-dwelling Iranian adults.
METHODS: We conducted a cross-sectional study on healthy Iranian adults using a convenience sampling technique. The short form of the Depression Anxiety and Stress Scale (DASS-21) was used to measure the outcome, and independent variables included body mass index (BMI), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), body adiposity index (BAI), and a body shape index (ABSI). The relationship between obesity and mental health was investigated using a multivariate logistic regression model. The non-linear dose-response relationships were evaluated using restricted cubic splines (RCS) with three knots. The Benjamini-Hochberg procedure was used to adjust for multiple testing.
RESULTS: In our study of 434 participants, females made up 52% of the participants, with a mean age of 38.57 years. In all, 54.6%, 53.9%, and 56.6% were classified as having anxiety, depression, and stress respectively. Logistic regression analysis showed that the odds of mental health components including anxiety, depression, or stress was not significantly different across the tertiles of the obesity indicators. We observed a significant dose-response relationship between BAI and ABSI and the risk of anxiety (PBenjamini-Hochberg 0.028 > Pdose-response 0.023) and stress (PBenjamini-Hochberg 0.028 > Pdose-response 0.003) but not depression (PBenjamini-Hochberg 0.014 < Pdose-response 0.018). The lowest risk for anxiety was observed in people with a BAI of 28% and ABSI equal to 0.079. The risk of stress seemed to increase beyond an ABSI of 0.086.
CONCLUSION: Our findings showed no direct linear association between obesity indices and anxiety. However, a dose-response relationship was observed between BAI and ABSI and the risk of anxiety and stress, indicating the need for further investigation.
OBJECTIVES: To evaluate the New Zealand clinical experience with the adjustable transobturator male system (ATOMS), a novel continence device in the management of all degrees of stress urinary incontinence (SUI), focusing on efficacy and safety outcomes.
PATIENTS AND METHODS: A retrospective review of all ATOMS devices placed between May 2015 and November 2020 was conducted. Severity of SUI was assessed (pad usage) before and after surgery. SUI was defined as mild (1-<3 pads/day), moderate (≥3-5 pads/day) or severe (>5 pads/day). The primary outcome measures considered were the overall success rate (improvement in pad use) and the dry rate (with dry defined as either no or 1 safety pad/day). The number of outpatient adjustments and total filling volumes were also documented in each case. Additionally, we documented incidence and severity of device complications and an analysis of treatment failures.
RESULTS: A total of 140 patients were reviewed, with the most common indication for ATOMS placement being SUI after radical prostatectomy (82.8%). Of the patients included, 53 (37.9%) had previous radiotherapy, with 26 (18.6%) patients having had a previous continence procedure performed. No intraoperative complications were noted. The median preoperative pad usage was 4 pads/day. After a median follow-up of 11 months, median postoperative pad usage reduced to 1 pad/day. In our cohort, 116 patients (82.9%) reported an improvement in their pad usage and were considered successful with 107 (76.4%) patients reporting themselves to be dry. Complications within the first 90-days after surgery occurred in 20 (14.3%) of patients.
CONCLUSION: Treatment of SUI with the ATOMS is safe and effective. The option of long-term, minimally invasive adjustment to respond to patient needs is a significant advantage.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to vascular surgery, and can be used in treating chronic obliterating diseases of lower extremity arteries. That is ensured by introduction of thrombocyte-enriched autoplasma containing polypeptide growth factors into an involved extremity. Said introduction is ultrasound aided from two points in inguinal and popliteal regions in amount 100 ml for each with distributing along the deep artery of thigh and popliteal artery and in adjacent muscles. ^ EFFECT: method allows stimulating development of collateral blood flow in an ischemic limb and improving arterial inflow from proximal to distal regions. ^ 1 ex
Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administraters to a mammal viral vectors that deliver genes expressing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis. Embodiments of the present invention are directed primarly, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF singaling through its receptor. Pathobiologic phenomena inlcude, but are not limited to, disease entities such as osteoprosis, Alzheimer's disease, diabetes mellitus (Type 1 and/or Type 2), infectious disease, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.
Volume support mode ventilation is a spontaneous mode where a target goal volume is set on the ventilator. This ventilatory strategy is dependent on patients spontaneously breathing and triggering (or activating) the ventilator to support the breath. The ventilator adjusts the amount of pressure support to deliver with each breath (i.e. if the patient's tidal volume is greater than the set target volume, then the ventilator will decrease the amount of pressure support in the subsequent breath to try to achieve the goal volume and vice versa). The respiratory rate is not set in this mode of ventilation and is dependent on the patient. For patients randomized to this mode, the goal tidal volume will be set at 6 cc/kg of ideal body weight (IBW).
From the preparation stage of the PAP-SMEAR ALDIRAN procedure to the completion of the application process that takes PAP-SMEAR, the virtual reality glasses for breathing exercise by clicking the youtube.com link (https://www.youtube.com/watch?v=Pddb09FAs68) after providing an internet connection with a smartphone for the image. will be provided.
Patients will participate in a psychosocial counseling session, 1 day/week for 20 weeks. Patients will be invited to participate in a progressive aerobic and resistance exercise program designed to achieve moderate and then vigorous levels of exercise, 5 days/week for 20 weeks.
After the pre-tests were completed, the pregnant women were divided into experimental and control groups. Pretest and postpartum 1st month and 4th month posttests were applied to the control group.
In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. In the literature, two cases of hyperkalemia in elderly patients have been reported after concomitant intake of sulfamethoxazole/trimethoprim and an angiotensin converting enzyme inhibitor.

It has been reported that sulfamethoxazole and trimethoprim may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. This interaction should be kept in mind when sulfamethoxazole and trimethoprim is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed.

Sulfamethoxazole and trimethoprim may inhibit the hepatic metabolism of phenytoin. Sulfamethoxazole and trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.

Sulfonamides can also displace methotrexate from plasma protein binding sites,thus increasing free methotrexate concentrations.
OBJECTIVE: The traditional drug delivery system is not much effective when treating chronopathological diseases like arthritis. Consequently, there is a gap in the market for a delivery system that can provide an explicit treatment following the chronopharmacology of this disorder. The present study is based on the objective to develop Eudragit coated dual release bilayer tablet designed by the quality by design (QbD) and based on the chronotherapeutic approach. The dual release tablet contained an immediate release layer of etoricoxib and a sustained release layer of thiocolchicoside.
MATERIAL AND METHOD: The quality target product profile (QTTP) of the formulation was established along with critical quality attributes (CQA). The optimization of the dual release layer was done using a three-level, three-factor Box-Behnken design. A total of thirteen formulations of etoricoxib (ET1-ET13) and thiocolchicoside (TH1-TH13) were developed based on the design composition of etoricoxib, sodium starch glycolate and sodium bicarbonate for the immediate release (IR) layer and thiocolchicoside, HPMC E5 LV and magnesium stearate for the sustained release (SR) layer respectively. The developed dual release layers were compressed to form a bilayer tablet. The bilayer tablets were further coated with pH-dependent polymer Eudragit S-100 to avoid drug release in upper GIT. The initial characterization and drug-excipient interaction studies were performed initially using infra-red (IR) spectroscopy and X-ray diffraction studies (XRD). Formulations showing good micrometric properties, disintegration and drug release were selected for final compression of bilayer tablets.
RESULT: Formulation ET13 showed the fastest drug release (88%) at 15minutes and quick disintegration time (21s). The sustained release thiocolchicoside tablet layer (TH1-TH13) had a hardness that varied from 4.01 to 4.45kg/cm2. Formulation TH12 had the highest hardness, whereas TH6 showed the lowest hardness. The sustained release layer showing 97.63% of drug release after 8hours was selected for the compression to bilayer tablet. The developed dual layer tablets were investigated for quality parameters like hardness, percentage friability, weight variation, disintegration and dissolution.
CONCLUSION: A high level of patient compliance is ensured through the current design as the patient does not need to get out of bed at night to take the medication.
Cooperation and networking are powerful tools in the combating against tropical diseases. Cooperation on a global scale is essential due to the transboundary nature of tropical diseases. Networking plays a pivotal role in facilitating such cooperation. Both cooperation and networking can foster innovation in disease control programmes. Collaborative research can lead to the development of new drugs and vaccines, while shared surveillance data can enable the early detection and control of disease epidemics. Therefore, consensus of cooperation and networking has been reached during the 7th Symposium on Surveillance-Response Systems Leading to Tropical Diseases Elimination, which reflected in the two documents, i.e., Consensus for Transboundary Tropical Diseases Control, and Action Consensus of the Network of WHO Collaborating Centres Related to NTDs. These documents will improve the efforts in the fighting against tropical diseases through collective actions to achieve the United Nations' Sustainable Development Goals (SDGs).